QIAGEN adds promising genomic biomarkers to pipeline
Mutations of SF3B1 gene indicate favorable prognosis for patients with bone marrow disorders
30-Jul-2014 -
QIAGEN N.V. announced it has acquired an exclusive global license to the biomarker SF3B1 from the University of Tokyo. SF3B1 is believed to play a critical role in the prognosis of patients with myelodysplastic syndromes (MDS), a group of hematological cancers in which bone marrow does not ...
biomarker
myelodysplastic syndromes
Qiagen
+1